Metastatic RCC

COSMIC-313: Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Phase: 3
Study Product: Cabozantinib with Nivolumab and Ipilimumab vs. Placebo with Nivolumab and Ibilimumab
Estimated Study Completion Date: June 2024 Identifier: NCT03937219

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember to talk to your healthcare providers first before making decisions about your plan of care.

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study. To learn more about our trials, call Jennifer at (843) 449-1010 ext. 316 or email us by filling out the form below.